The design and debottleneck of plants often require multiple iterations of engineering and capital expenditure (CAPEX) analysis. No matter how well an asset is designed, once operational, new variables come into play allowing for further optimization opportunities to arise. The handoffs between design, construction and operations bring new wrinkles to the entire system. What may seem like an inconsequential decision in one area may have a significant impact in another.

Digital transformation to the Pharma 4.0 paradigm moves forward in process development and clinical and commercial manufacturing.

How digital transformation helps pharma leaders navigate 3 major industry headwinds.

Methane discharges are seen as one of the main causes of carbon emissions. Consequently, the world is enforcing stricter regulations that confine flaring practices. Still, methane leaks occur from oil production during periods of distressed operations.

Do you have an accurate, enterprise view of your emissions? Are you taking the most cost-effective path to net zero? How do you balance sustainability with producing affordable energy or chemical products?

While biotherapeutics is one of the fastest growing sectors in life sciences today, the tech transfer process still takes many years. Regulatory approval can be time consuming—from conducting clinical trials to achieving a validated process design.

AspenTech has been at the forefront of pioneering technologies, helping asset-intensive industries increase operational efficiencies so they can produce more while using fewer natural resources.

This FAQ document shares answers to questions from the webinar, “Advance Biopharma Tech Transfer Using Process Modeling and Simulation.”

Aspen Technology Advances BPCL's Sustainability Initiative

Carbon8 and AspenTech Partner to Reduce Emissions in Hard-to-Abate Sectors